The trial, sponsored by Columbia University, aims to evaluate the safety and efficacy of a combination therapy involving oral decitabine-cedazuridine and thioguanine in patients with relapsed or refractory AML. The market for AML therapies is significant, with a high unmet need for effective treatments, particularly in relapsed cases where current options yield low response rates. The withdrawal of the trial due to difficulties in enrollment may indicate challenges in patient recruitment, potentially impacting the commercial viability of this combination therapy. Competitively, the landscape includes established therapies and emerging agents, necessitating a robust differentiation strategy for any successful outcomes from this trial.